Browse the evidence

Retatrutide, a triple GLP-1/GCGR/GIP receptor agonist, produces significant weight loss (-22.1% placebo-subtracted) in individuals with obesity.

Retatrutide is an emerging triple-agonist injection that targets GLP-1, GCGR, and GIP receptors to produce significant weight loss. It is currently in phase II trials, so long-term safety data is not yet fully established, but early results show high efficacy.

Tirzepatide produces clinically significant reductions in HbA1c and body weight in real-world type 2 diabetes patients, with greater efficacy observed in GLP-1 receptor agonist-naïve patients compared to those switched from prior GLP-1 therapy.

For patients with Type 2 Diabetes, tirzepatide is a highly effective once-weekly injection for lowering blood sugar and losing weight. While real-world results are slightly less dramatic than clinical trials, they are still clinically significant. Patients who have never used GLP-1 agonists before tend to see the best results, but those switching from other GLP-1 drugs also benefit from improved A1C and weight loss.

Chickpeas stimulate satiety hormones (GLP-1, PYY) and reduce appetite, though meta-analysis of insulin response is inconsistent.

Use chickpeas to help manage hunger. They trigger satiety hormones like PYY and GLP-1. If you are sensitive to fiber, try chickpea flour or puree rather than whole beans to improve digestibility.

Daily oral administration of 4 mg capsaicinoids (as Capsicum annuum extract) during a 12-week caloric restriction prevents the decline of beneficial plasma endocannabinoidome mediators (specifically N-oleoyl-ethanolamine, N-linoleoyl-ethanolamine, and 2-oleoyl-glycerol) and increases the relative abundance of the genus Flavonifractor in reproductive-aged women with overweight/obesity.

If you are restricting calories to lose weight, adding 4mg of capsaicinoids daily (via standardized extract) may help preserve beneficial metabolic signaling molecules (like OEA) and support a healthier gut microbiome profile (specifically increasing Flavonifractor) compared to dieting alone. This is particularly relevant for women with overweight/obesity. Expect potential mild GI side effects.

Weight loss achieved through GLP-1 agonists or lifestyle interventions improves the severity and treatment response of immune-mediated skin diseases like psoriasis and hidradenitis suppurativa.

If you have psoriasis or hidradenitis suppurativa, losing weight can directly reduce the severity of your skin lesions and improve how well your treatments work. This is because excess fat tissue drives inflammation. Managing your weight helps calm the underlying immune response.

Adding DPP4 inhibitors (e.g., sitagliptin) to metformin significantly improves glycemic profiles (fasting blood sugar and HOMA-IR) in women with PCOS compared to metformin alone.

If metformin alone isn't controlling your blood sugar or insulin resistance, adding a DPP4 inhibitor (like sitagliptin) is a clinically supported next step. This combination targets glucose metabolism more effectively than metformin alone in PCOS patients.

Adding Thiazolidinediones (TZDs) to metformin has the most significant influence on lipid levels (specifically lowering LDL and improving lipid profiles) in women with PCOS.

If lipid management is a primary concern in your PCOS treatment, adding a TZD (like pioglitazone) to metformin is the most effective strategy among the reviewed drugs for improving your lipid profile.

Efpeglenatide, a long-acting GLP-1 receptor agonist administered once weekly or every two weeks, significantly reduces body weight and improves glycemic control (reverting pre-diabetes to normoglycemia) in patients with obesity or overweight without type 2 diabetes, regardless of baseline BMI, age, or pre-diabetes status.

If you have obesity or are overweight with health issues but no diabetes, efpeglenatide is a once-weekly (or bi-weekly) injection that can help you lose weight and improve your blood sugar control. It works regardless of your age or how much you weigh. You should also try to eat about 500 fewer calories a day and be more physically active. Common side effects are stomach-related, like nausea, but these often get better over time.

In severely obese nondiabetic males, a decrease in the serum cortisol-to-cortisone (F/E) ratio following significant weight loss is independently associated with a reduction in systolic blood pressure.

For severely obese men, losing significant weight (15% or more) through a structured program not only lowers blood pressure but also shifts how the body processes cortisol. This shift, measured by the cortisol-to-cortisone ratio, is a key driver of that blood pressure improvement. Monitoring this metabolic change might help predict who benefits most from weight loss interventions for hypertension.

Combination incretin therapies (GLP-1/GIP, GLP-1/Glucagon, or GLP-1/GIP/Glucagon) produce superior weight loss and glycemic control compared to monotherapy GLP-1 receptor agonists by targeting multiple hormonal pathways simultaneously.

If standard GLP-1 drugs (like Ozempic or Saxenda) aren't delivering enough weight loss or metabolic improvement, combination therapies like Tirzepatide (Mounjaro/Zepbound) or Cotadutide target multiple hormones (GLP-1, GIP, Glucagon) to potentially achieve greater weight loss and better blood sugar control. These are typically weekly injections, though oral versions exist. Expect potential gastrointestinal side effects like nausea, which often improve over time. Consult a doctor to see if you qualify for these newer, more potent treatments.

Dual GLP-1/Glucagon receptor agonists (e.g., Cotadutide, Oxyntomodulin) promote weight loss by combining appetite suppression (GLP-1) with increased energy expenditure (Glucagon).

Drugs like Cotadutide combine two hormones: GLP-1 (which reduces appetite) and Glucagon (which increases energy expenditure). This dual action can lead to weight loss, potentially greater than GLP-1 alone. These are daily injections. Be aware of potential gastrointestinal side effects and monitor heart rate, as glucagon can increase heart rate. Discuss with your doctor if this mechanism is appropriate for your health profile.

Combining GLP-1 receptor agonists with SGLT2 inhibitors produces additive weight loss by reducing caloric intake (GLP-1) and increasing caloric excretion via glucosuria (SGLT2).

Combining a GLP-1 drug (like Byetta/Bydureon) with an SGLT2 inhibitor (like Farxiga/Jardiance) can lead to greater weight loss than either drug alone. The GLP-1 reduces hunger, while the SGLT2 causes you to excrete sugar in your urine, burning calories. This combination is often used for Type 2 Diabetes but can aid weight loss. Be mindful of potential genital yeast infections or UTIs, which are common side effects of SGLT2 inhibitors.

Bariatric surgery and incretin-based therapies (GLP-1 RAs, tirzepatide) reduce pancreatic disease burden and improve metabolic profiles relevant to pancreatic pathology.

If you are considering weight loss medications like GLP-1 agonists (e.g., semaglutide) or dual agonists (e.g., tirzepatide), current evidence suggests they do not increase the risk of pancreatitis or pancreatic cancer. They may actually help reduce pancreatic inflammation and disease burden by improving metabolic health.

Post-exercise consumption of 20g whey protein (WP), casein (CAS), or 80:20 WP/CAS blends increases plasma branched-chain amino acid (BCAA) concentrations and reduces delayed onset muscle soreness (DOMS) compared to placebo, but combining WP and CAS does not enhance BCAA profiles or muscle recovery beyond consuming WP alone.

If you are looking to reduce muscle soreness after a heavy workout, taking 20g of whey protein, casein, or an 80:20 blend immediately after training will help more than a placebo. However, there is no need to buy expensive 'blend' supplements; pure whey protein provides the same amino acid spike and recovery benefits as the blend. Save your money and stick to whey protein.

Replacing dietary fat with high-glycemic index (GI) carbohydrates increases the prevalence of hypertriglyceridemia and low HDL-cholesterol, particularly in non-obese individuals.

If you eat a high-carbohydrate diet, the quality of those carbohydrates matters significantly for your blood fats. Replacing fats with high-glycemic index carbs (like white rice or refined grains) is linked to higher triglycerides and lower 'good' HDL cholesterol. This effect is particularly strong if you are not overweight. Focus on low-GI carbohydrates and healthy fats rather than simply reducing fat intake.

Semaglutide (SEM) is the most popularly searched GLP-1 receptor agonist for weight loss, yet it exhibits the lowest proportion of severe adverse drug reactions (ADRs) compared to other GLP-1 RAs, despite having the highest absolute number of spontaneous safety reports.

Semaglutide is the most searched GLP-1 for weight loss, leading to high prescription volumes and consequently the highest number of adverse event reports. However, data shows it actually has the lowest rate of severe adverse reactions compared to other GLP-1 drugs. The high volume of reports is likely due to its popularity and off-label use driven by social media, rather than inherent high severity. Users should be aware that off-label use increases risks like overdose and should be monitored by a healthcare professional.

A significant proportion of patients subscribe to digital weight-loss services primarily to access GLP-1 receptor agonist (GLP-1 RA) medications after failing stand-alone lifestyle interventions, supporting the critique that some DWLSs function primarily as medication access pathways.

If you have tried diet and exercise without success, you are not alone. Digital services that offer GLP-1 medications may be a viable option, but ensure they provide medical supervision and are not just a direct-to-consumer pharmacy.

Weight loss interventions (pharmacological or bariatric) in sarcopenic obesity can improve muscle-specific strength and functional parameters despite absolute muscle mass loss, potentially reversing the sarcopenic obesity diagnosis.

If you are considering weight loss medication for obesity, discuss the potential benefits for muscle function. Even if you lose some muscle mass, your strength and ability to function may improve due to reduced fat in muscles and better metabolism. This can reverse sarcopenic obesity.

Consuming a protein- and leucine-enriched bar (containing ~16g protein and 1.5g free leucine) two hours after a low-protein breakfast increases peak plasma leucine and essential amino acid exposure to levels comparable to a high-protein breakfast, while significantly reducing hunger and increasing fullness in older adults.

For older adults who struggle to eat large breakfasts, adding a small, leucine-enriched protein bar about two hours after a light breakfast can boost muscle-building signals and keep hunger away just as effectively as a much larger, high-protein breakfast. Look for bars with ~1.5g of free leucine and ~16g of mixed protein.

Treatment with GLP-1 receptor agonists (semaglutide or dulaglutide) significantly reduces biochemical markers of liver fibrosis (FIB-4 score) and inflammation (De Ritis ratio) in patients with type 2 diabetes and MASLD over 180 days.

For patients with Type 2 Diabetes and fatty liver disease, GLP-1 agonists like semaglutide or dulaglutide (taken weekly) can significantly improve liver health markers (specifically fibrosis risk scores) over 6 months, even without changes to diet or exercise. This suggests these drugs offer liver-specific benefits beyond just weight loss or blood sugar control.

Once-weekly subcutaneous semaglutide (1 mg) produces clinically significant weight loss (median 4.4% in diabetics, 3.4% in non-diabetics) and improves glycemic control (HbA1c reduction of 0.4%) in patients with type 2 diabetes over 6 months.

If you have Type 2 Diabetes, once-weekly semaglutide (starting at 0.25mg and titrating up to 1mg) is a proven tool for losing weight (average ~4-5%) and improving blood sugar control. It works by mimicking a gut hormone to slow digestion and regulate insulin. While nausea is common, it is usually mild. It is not a magic bullet; you still need to eat a balanced diet, but the drug significantly aids the process.

Semaglutide (1 mg) promotes significant weight loss and improves BMI in patients without Type 2 Diabetes, without causing significant changes in HbA1c or hypoglycemia risk.

If you do not have diabetes but struggle with weight, semaglutide (1 mg weekly) can help you lose about 3-4% of your body weight. Because it works based on blood sugar levels, it does not typically cause dangerous low blood sugar (hypoglycemia) in non-diabetics. It is used off-label for this purpose but is supported by clinical guidelines.

Semaglutide improves cardiometabolic risk factors, including diastolic blood pressure, in patients without diabetes, while maintaining renal stability in both diabetic and non-diabetic populations.

Semaglutide offers cardiovascular benefits beyond weight loss, such as lowering diastolic blood pressure in non-diabetics. It also appears to protect kidney function (stable creatinine and albumin/creatinine ratio) in both diabetic and non-diabetic patients, making it a favorable option for those with cardiometabolic risks.

Among obese individuals, frequent or daily alcohol consumption and extra salt intake are independent risk factors for metabolic syndrome, whereas physical inactivity and sugar-sweetened drink consumption do not show statistically significant associations.

If you are obese, managing your weight is crucial, but it is not the only lever. This research suggests that for obese individuals, cutting out daily alcohol and reducing extra salt at the table are critical, specific actions to lower metabolic syndrome risk, potentially more so than just increasing exercise or cutting sugary drinks in this specific demographic.